The Pharmacy Times® Multiple Myeloma Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that forms in a type of white blood cell.
May 7th 2024
CAR T-cells specifically targeting FCRL5, when integrated with IL-15, may improve cytotoxicity, thereby enhancing the therapeutic potency of these cells.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strategies
1.0 Credit / Oncology, Hematologic Cancer
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Practice
1.0 Credit / Hematologic Cancer, Oncology
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and Safety Measures
1.0 Credit / Hematologic Cancer
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operational Efficiency in Multiple Myeloma
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based Care
1.0 Credit / Hematologic Cancer, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success
1.0 Credit / Hematologic Cancer
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell Therapies and Bispecific Antibodies in Multiple Myeloma
0.75 Credit / Oncology, Hematologic Cancer
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
The Impact of the FDA's Project Optimus on Oncology Drug Trials
October 1st 2021In an interview with Pharmacy Times®, Maria Whitman, Global Head of the Pharmaceutical and Biotech Practice at ZS, discusses the FDA’s Project Optimus, the FDA’s new guidance addressing dose optimization issues in oncology clinical trials, and how it has impacted drug manufacturers.
Watch
Novel Small Molecule Drugs for the Treatment of Triple-Class Refractory Myeloma
September 29th 2021Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
Read More
Pharmacist Medication Insights: Darzalex Faspro for Multiple Myeloma
August 16th 2021Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.
Watch
Ruxolitinib Improves Outcomes for Certain Patients With GvHD
July 27th 2021According to the investigators, treatment with ruxolitinib resulted in a significant improvement in ORR after 24 weeks, with an ORR of 49.7% in the ruxolitinib arm compared to 25.6% in the best available therapy arm.
Read More
FDA Approves First Anti-BCMA CAR T-Cell Therapy for Relapsed, Refractory Multiple Myeloma
March 29th 2021In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.
Read More
FDA Approves Selinexor Combination Treatment for Certain Patients With Multiple Myeloma
December 19th 2020Selinexor (Xpovio; Karyopharm Therapeutics Inc.) in combination with bortezomib (Velcade; Takeda) and dexamethasone was approved for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.
Read More
Preliminary Results of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma
December 10th 2020Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.
Read More
Using Belantamab Mafodotin and Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma
December 9th 2020Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Watch